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Abstract Amino-terminally truncated parathyroid hormone
(PTH) fragments are detected to differing degrees by first-
and second-generation immunometric PTH assays (PTH-
IMAs), and acute changes in serum calcium affect the
proportion of these fragments in circulation. However, the
effect of chronic calcium changes and different vitamin D
doses on these PTH measurements remains to be defined.
In this study, 60 pediatric dialysis patients, aged 13.9±
0.7 years, with secondary hyperparathyroidism were ran-
domized to 8 months of therapy with oral vitamin D
combined with either calcium carbonate (CaCO3)o r
sevelamer. Serum phosphorus levels did not differ between
groups. Serum calcium levels rose from 9.3±0.1 to 9.7±
0.1 mg/dl during CaCO3 therapy (p<0.01 from baseline)
but remained unchanged during sevelamer therapy. In the
CaCO3 and sevelamer groups, baseline serum PTH levels
(1st PTH-IMA; Nichols Institute Diagnostics, San Clem-
ente, CA) were 964±75 and 932±89 pg/ml, and levels
declined to 491±55 and 543±59 pg/ml, respectively
(nonsignificant between groups). Patients treated with
sevelamer received higher doses of vitamin D than those
treated with CaCO3. The PTH values obtained by first- and
second-generation PTH-IMAs correlated closely through-
out therapy and the response of PTH was similar to both
PTH-IMAs, despite differences in serum calcium levels.
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Introduction
Parathyroid hormone (PTH) levels rise as renal function
declines, and these levels are widely used to assess bone
turnover and to guide therapy for renal osteodystrophy [1].
Different mid- and C-terminal fragments of the intact PTH
molecule accumulate in patients with chronic kidney disease
(CKD), complicating the accuracy of the radioimmunoassay
PTH measurements in the assessment of parathyroid gland
activity [2]. The development of the two-site immunometric
assays (IMAs) for the detection of PTH has reduced cross-
reactivity with small PTH fragments, yet large amino-
terminal truncated PTH fragments (ntPTH) continue to
cross-react with first-generation immunometric PTH-IMAs
(1st PTH-IMAs) [3–6], thus overestimating the levels of
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e-mail: kwesseling@mednet.ucla.edubiologically active PTH in circulation. At least one of those
fragments, PTH(7-84), has been shown to antagonize the
calcemic actions of the full-length molecule in vivo [7–9],
whichmayconfoundtherelationshipbetweenPTHlevelsand
bone turnover in individuals with CKD. Second-generation
immunometric PTH assays (2nd PTH-IMAs) detect exclu-
sively the full-length PTH(1-84) molecule and thus more
accuratelyreflect the concentrationofbiologicallyactivePTH
[10]. While ntPTH cannot be measured selectively by
currently available assays, an estimation of their abundance
may be obtained by subtracting the value obtained with the
2nd PTH-IMA from the value obtained with the 1st PTH-
IMA [11, 12]. This estimate has been postulated by some
investigators to have potential clinical significance in the
diagnosis of renal osteodystrophy [11, 13], although its
utility has not been substantiated by others [12, 14].
Changes in serum calcium, as occur during therapy with
calcimimetic agents, have been associated with altered
proportions of PTH detected by the 1st and 2nd PTH-IMAs
[15], suggesting that therapies which affect serum calcium
levels may modify the proportions of PTH(1-84) to ntPTH in
circulation. Furthermore, the short-term use of different
vitamin D analogues has also been associated with different
proportions of PTH(1-84) to ntPTH [16]. Inrecentyears,non-
calcium-containing phosphate binders used in conjunction with
vitamin D sterols have been shown to control serum phosphate
concentrations and the skeletal lesions of secondary hyperpara-
thyroidism as effectively as calcium-based binders, without
increasing serum calcium levels [17]. Although PTH levels, as
determined by 1st PTH-IMA, have been found to decline to a
similar degree regardless of type of phosphate-binding therapy
[17] ,t h er e s p o n s eo fP T Hm e a s u r e db yt h e2 n dP T H - I M A ,
i.e. excluding the detection of large amino-terminally truncat-
ed PTH fragments, to different phosphate binder therapies
remains unknown. Thus, our study was designed to evaluate
the relative changes in serum PTH levels, as measured by the
1st and 2nd PTH-IMAs, during treatment of secondary
hyperparathyroidism with either calcium carbonate (CaCO3)
or sevelamer in combination with active vitamin D sterols in
pediatric dialysis patients.
Methods
The patients included in this study are part of an ongoing
clinical trial designed to evaluate the effects of two vitamin D
analogues and two phosphate binders on the control of the
skeletal lesions of secondary hyperparathyroidism, as previ-
ously reported [17]. Briefly, potential subjects, aged 2–
20 years, treated with continuous cycling peritoneal dialysis
(CCPD) (2.5 mEq/l calcium dialysate) and with serum PTH
levels [1st PTH-IMA; Nichols Institute Diagnostics, San
Clemente, CA; hereafter referred to as Nichols] >400 pg/ml
were considered as potential candidates for the study. After a
4-week withdrawal period from vitamin D therapy, patients
were admitted to the UCLA General Clinical Research
Center, and bone biopsies were obtained from the anterior
iliac crest using a modified Bordier trephine after double
tetracycline labeling; bone quantitative histomorphometry
was performed as previously described [18]. Those subjects
who had bone histological findings consistent with second-
ary hyperparathyroidism (i.e. high bone formation rates and/
or marrow fibrosis) [19] were randomized into one of four
treatment arms for 8 months using a 2×2 study design:
group 1, doxercalciferol + CaCO3 (n=16); group 2,
doxercalciferol + sevelamer (n=14); group 3, calcitriol +
CaCO3 (n=16); group 4, calcitriol + sevelamer (n=14).
Exclusion criteria were: history of poor medication compli-
ance, parathyroidectomy within the past 12 months, treat-
ment with prednisone, other immunosuppressive agent(s) or
growth hormone within the preceding 6 months, or other
bone pathology. During treatment, patients were removed
from the study per protocol in the event of either renal
transplantation or medication noncompliance, defined as a
serum phosphorus level >7 mg/dl for 3 consecutive months.
The study was approved by the UCLA Human Subject
Protection Committee and informed consent was obtained
from all patients and/or parents.
Study protocol
The initial dose of vitamin D was determined by the
baseline 1st PTH-IMA (Nichols) concentration, and doses
were titrated upwards monthly based on PTH, calcium, and
phosphorus values. Patients with 1st PTH-IMA (Nichols)
values <600 pg/ml received an initial vitamin D sterol dose
of either 0.5 μg (calcitriol) or 2.5 μg (doxercalciferol);
those with values >600 pg/ml received 1 μg (calcitriol) or
5 μg (doxercalciferol). All doses were given Monday,
Wednesday, and Friday orally at bedtime [17]. The PTH
target values were between 300 and 400 pg/ml (1st
generation, Nichols), and vitamin D therapy was held for
serum calcium values >10.2 mg/dl or serum phosphorus
levels >6 mg/dl. Phosphate-binding therapy, in the form of
CaCO3 o rs e v e l a m e r ,w a st i t r a t e dt om a i n t a i ns e r u m
phosphorus levels between 4.0 and 6.0 mg/dl [17].
Serum levels of calcium, albumin, and phosphorus were
obtained at baseline and biweekly throughout the 8-month
course of the study; serum alkaline phosphatase and PTH
levels were determined monthly. Biochemical measurements
of calcium, albumin, phosphorous, and alkaline phosphatase
were determined as previously described [17]. Levels of PTH
were determined in plasma by three separate assays: two 1st
PTH-IMAs by different manufacturers (Nichols, San Clem-
ente, CA; Immutopics, San Clemente, CA) and one 2nd
PTH-IMA (Immutopics). The characteristics of these assays
1356 Pediatr Nephrol (2009) 24:1355–1361have been described in earlier reports [10, 12]. Serum
calcium levels were corrected for serum albumin levels by
the formula: corrected calcium = measured calcium + [0.8 ×
4 – (serum albumin)]. While 1st PTH-IMA (Nichols) values
were used for vitamin D therapy titration, plasma samples for
1st and 2nd PTH-IMA (Immutopics) were stored at –80°C,
and the analyses were performed in batches upon completion
of the study period. The ratio of PTH(1-84)/ntPTH was
calculated as the measurement of 2nd PTH-IMA (Immu-
topics)/[1st PTH-IMA (Immutopics) – 2nd PTH-IMA
(Immutopics)], as previously described [11, 12, 14].
Statistical analysis
The power of the overall trial was calculated based on a
change in bone formation rate from baseline [17]; the
biochemical data presented in this study were pre-
determined secondary endpoints of the study. All data from
study subjects were evaluated on an “intent-to-treat” as well
as on a “per-protocol” basis. Mean and standard error were
used to summarize the outcomes for each treatment group
at each time point. Baseline determinations between the two
phosphate binder groups were compared using the t test.
The results of the descriptive analyses demonstrated a
difference in the data from the initial 4-month period to the
last 4 months: changes in serum levels of calcium, PTH,
and alkaline phosphatase were observed during the first
4 months, while values were stable during the last 4 months
of the study. Therefore, the mean values for each treatment
group in the last 4 months were estimated, and comparisons
between treatment groups were performed. A mixed model,
including treatment, time, and treatment by time interac-
tions, was developed to compare differences between the
two treatment groups and average changes from baseline
within treatment groups. Loess local regression fit lines
with 95% confidence intervals (95% CI) were also used to
assess differences, as determined by the percentage change
from baseline, between different PTH assays. Spearman
correlation coefficients were calculated using mixed model
coefficients throughout the course of the study. The
statistical analyses were performed using SAS software
(SAS Institute, Cary, NC), and all tests were two-sided with
a significance level of p<0.05.
Results
Study participants
A total of 60 patients (30 males, 30 females) aged 13.9±
0 . 7y e a r sw e r ee n r o l l e di nt h es t u d y .T h ec a u s e so fe n d -
stage kidney disease were equally divided between
glomerular disease, obstruction/dysplasia, and unknown
etiology. The average time on dialysis was 12±2 months.
Eleven subjects had previously undergone renal transplan-
tation; none of these had residual graft function or were on
immunosuppressive therapy at the time of the study. Fifty-
one patients completed the study, while nine discontinued
the study early (five from group 1, two from group 2, one
from group 3, and one from group 4) due to renal
transplantation (five patients) and medication non-
compliance (four patients) as per protocol. As previously
described [17], preliminary analysis revealed no inter-
actions between the two vitamin D analogues with
respect to any biochemical parameters. Thus, our study
was confined to comparisons between the two phos-
phate binders. No differences in outcomes were ob-
served between intent-to-treat and per-protocol analyses;
consequently, only results for the intent-to-treat analysis
are described here.
Changes in serum phosphorus, calcium, and alkaline
phosphatase levels according to the type
of phosphate-binding agent
Baseline serum phosphorus levels were 6.4±0.1 and 6.2±
0.2 mg/dl (nonsignificant, NS) in CaCO3- and sevelamer-
treated patients, respectively, and the values did not differ
between these groups throughout the course of the study
(Fig. 1). Initial serum calcium levels were 9.3±0.1 mg/dl in
both the CaCO3 and sevelamer groups. Serum levels of
calcium rose during the first 4 months and then plateaued in
the CaCO3 treatment group; by contrast, values remained
unchanged from baseline in the sevelamer group (Fig. 1).
Final serum calcium levels were 9.7±0.1 mg/dl (CaCO3)( p<
0.01 from baseline) and 9.2±0.2 mg/dl (sevelamer) (NS from
baseline, p<0.05 between groups) (Fig. 1). The initial
calcium–phosphorus ion products were 51.6±1.6 and 50.7±
1.8 in the CaCO3 and sevelamer groups, respectively (NS),
Fig. 1 Serum phosphorus (squares) and calcium (circles) levels
throughout the study in patients treated with CaCO3 (closed
symbols) versus sevelamer (open symbols). The asterisk indicates a
significant change from baseline (p<0.01), while the double dagger
indicates a difference between the sevelamer and CaCO3 treatment
groups (p<0.01)
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between groups). Forty-eight episodes of hypercalcemia
(serum calcium≥10.2 mg/dl) occurred in the CaCO3 treat-
ment group compared with 17 episodes in the sevelamer
group (p<0.01).
Baseline serum alkaline phosphatase levels were 373±
38 versus 424±64 IU/l (CaCO3 vs. sevelamer, NS), and the
values declined to 289±42 and 361±57 IU/l in the two
groups respectively (p<0.01 from baseline in both groups;
NS between groups).
Changes in PTH levels according to the type
of phosphate-binding agent
Prior to therapy, PTH values, as determined by the 1st
PTH-IMA (Nichols), were 964±75 and 933±89 pg/ml in
the CaCO3 and sevelamer treatment groups, respectively
(NS). Irrespective of phosphate binder, PTH values de-
creased between months 3 through 5 of therapy, reaching a
plateau by month 6 (Fig. 2). Average PTH levels during the
last 4 months of therapy were 491±55 and 544±75 pg/ml
in the CaCO3 and sevelamer groups, respectively (p<0.01
from baseline in both groups; NS between groups), which
is equivalent to an overall 49±7% and 42±6% decline,
respectively, in the two groups (p <0.01 from baseline in
both groups; NS between groups).
At study entry, serum PTH levels as measured by the 1st
PTH-IMA (Immutopics) were 839±73 and 769±69 pg/ml
in CaCO3- and sevelamer-treated patients, respectively
(NS). The levels by this assay behaved similarly to those
measured by the 1st PTH-IMA by Nichols, with a similar
rate of decline during treatment and similar final values
(Fig. 2). Serum PTH values determined by the 2nd PTH-
IMA (Immutopics) were initially 524±51 and 495±
65 pg/ml in the CaCO3 and sevelamer treatment groups,
respectively (NS). Average levels during the last 4 months
of therapy were 239±44 and 261±32 pg/ml,
corresponding to a 54±11% and 47±8% decline (CaCO3
vs. sevelamer), respectively (p<0 . 0 1f r o mb a s e l i n ei nb o t h
groups; NS between groups). The time course of decline
in PTH levels as measured by the 2nd PTH-IMA
paralleled that of the 1st PTH-IMAs (Fig. 2).
Throughout the course of the study, the PTH values
as determined by the different assays were highly
correlated: 1st PTH-IMA (Nichols) and 1st PTH-IMA
(Immutopics), r=0.81, p<0.01; 1st PTH-IMA (Nichols)
and 2nd PTH-IMA (Immutopics), r=0.81, p<0.01; 2nd
PTH-IMA (Immutopics) and 1st PTH-IMA (Immutopics),
r=0.93, p<0.01.
The ratio of PTH(1-84)/ntPTH did not differ between
groups during the course of the study. Average values
were 1.9±0.4 and 1.6±0.2 in the CaCO3 and sevelamer
groups, respectively, at the start of the study (NS between
groups). Average values during the last 4 months of the
study were 1.2±0.1 and 1.5±0.2 in the two groups,
respectively (NS between groups; NS from baseline).
Despite no differences in the ratio of PTH(1-84)/ntPTH
between treatment groups, patients with lower serum
calcium levels, defined as levels <9.5 mg/dl, had higher
ratios of PTH(1-84)/ntPTH during therapy for secondary
hyperparathyroidism, as has been previously reported
[15]. In blood samples in which the serum calcium value
was ≥9.5 mg/dl, the ratio of PTH(1-84)/ntPTH was 1.1±
0.2; when serum calcium values were <9.5 mg/dl, values
of PTH(1-84)/ntPTH were 1.6±0.2 (p<0.05).
Vitamin D dosage
Throughout the course of the study, the average dose of
vitamin D sterol in patients receiving doxercalciferol was
4.8±0.6 and 5.1±0.5 μg in the CaCO3 and sevelamer
treatment groups, respectively (NS); the average calcitriol
Fig. 2 Serum parathyroid hormone (PTH) values throughout the
course of the study in patients treated with CaCO3 (a) and those
treated with sevelamer (b). PTH levels were determined by the first-
generation immunometric assay by Nichols (1st PTH-IMA; closed
diamonds) and by the 1st PTH-IMA (open diamonds) and second-
generation (2nd) PTH-IMA (closed triangles) by Immutopics. The
asterisk indicates a significant (p<0.01) decrease from baseline
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sevelamer groups, respectively (NS). No differences were
found when the dose was normalized by patient weight.
The amount of administered vitamin D sterol increased
monthly during the first 4 months in response to serum
PTH, calcium, and phosphorus levels, reaching stable
dosage in the last 4 months of the study at a time when
the goal biochemical values were maintained. In order to
compare maintenance doses of vitamin D between patients
treated with CaCO3 and those treated with sevelamer, we
converted doxercalciferol dose to a calcitriol equivalent
dose (doxercalciferol dose/5) [20]. During the initial
4 months of the study (the titration phase), there was no
difference in the amount of vitamin D sterol administered to
patients treated with CaCO3 versus those receiving seve-
lamer. However, during the last 4 months of therapy, when
doses were stable, CaCO3-treated patients received 3.5±
0.7 μg/dose, while the sevelamer group received 5.7±
0.7 μg/dose of calcitriol equivalent (p<0.05).
Discussion
The results of this analysis indicate that an equivalent
degree of PTH reduction and phosphate control was
achieved during therapy for secondary hyperparathyroidism
when calcitriol or doxercalciferol, given orally three times
per week, was used in conjunction with either CaCO3 or
sevelamer. This reduction in PTH levels occurred despite
differences in serum calcium levels and differences in the
amount of administered vitamin D sterol. Serum PTH
determinations by both 1st PTH-IMAs were higher than
those measured by the 2nd PTH-IMA over a wide range of
values, with the 2nd PTH-IMA values being 40–60% lower
than those obtained by the 1st PTH-IMA; this result is
consistent with previous reports [11, 12, 14, 15]. However,
there was no difference in the percentage change of PTH by
any of the three assays, and final values were similar,
regardless of the type of therapy. An equivalent degree of
correlation was found between the three assays despite
different vitamin D sterol and phosphate binder therapies,
similar to the correlation observed between assays during
treatment with calcimetics [15]. The ratio of PTH(1-84)/
ntPTH did not change throughout the course of the study,
and there were no differences observed between the CaCO3
and sevelamer treatment groups whether patients received
calcitriol or doxercalciferol. However, the average PTH(1-
84)/ntPTH ratio was consistently higher in patients with
lower serum calcium levels, defined as serum calcium
levels <9.5 mg/dl, as has been previously described [15],
suggesting either that more PTH(1-84) and/or fewer ntPTH
fragments are being generated by the parathyroid gland in
these patients.
Although the results of the analysis reported here do not
show any differences in the response of different PTH
assays to vitamin D sterol and phosphate binder therapy, it
is possible that differences may be detectable in a larger
patient population. We found no differences in the rates of
PTH change, as assessed by the three different assays, from
baseline; however, we have previously reported that the
current treatment protocol results in a >50% decrease in
bone turnover [17]. Thus, the large change in bone
formation rate, combined with the lack of difference in
PTH assays in the current analysis, suggests that any
difference in the prediction of bone by the three assays
would likely be of minimal clinical significance.
This study reconfirmed that serum calcium levels
increase during therapy with calcium-based binders while
remaining unchanged in patients treated with sevelamer
[17, 21–23]. In addition, episodes of hypercalcemia were
more frequent in patients receiving therapy with CaCO3.
Indeed, final serum calcium levels in those treated with
vitamin D and sevelamer remained unchanged during
therapy and were equivalent to those observed in patients
treated with calcimimetic agents [15, 24]. Therapy with
sevelamer thus allowed for the use of higher doses of
vitamin D and may widen the margin of safety of vitamin D
therapy by allowing effective control of PTH secretion
without inducing hypercalcemia, a finding which has
potential implications in the prevention of vascular calcifi-
cations attributed to therapy with active vitamin D sterols
[25]. Interestingly, however, the same degree of PTH
suppression was observed by all three PTH assays [17],
regardless of the type of phosphate-binding agent, the
serum calcium levels, and the vitamin D sterol type.
While serum levels of PTH, as measured by both first-
and second-generation IMAs (Nichols) have been shown to
correlate throughout therapy with calcitriol and CaCO3 [6],
this is the first study to compare the response of the 1st and
2nd PTH-IMAs and the ratio of PTH(1-84)/ntPTH to
therapy with different phosphate binders and active vitamin
D sterols in patients with secondary hyperparathyroidism.
Changes in the ratio of PTH(1-84)/ntPTH is consistent with
results from short-term calcium infusion studies [10]a s
well as with long-term changes associated with the use of
calcimimetic agents in hemodialysis patients. Long-term
follow-up demonstrated that lower serum calcium concen-
trations (<9.5 mg/dl) were associated with a greater ratio of
PTH(1-84)/ntPTH when compared with serum calcium
concentrations >9.5 mg/dl [15]. This difference in the ratio
may be attributable to higher PTH(1-84) levels, to lower
ntPTH levels, or to a combination of both in patients with
lower serum calcium levels. Although in the study reported
here we did not detect a difference in serum PTH(1-84)
levels based on serum calcium levels, a larger sample size
may have revealed some differences in these values. On the
Pediatr Nephrol (2009) 24:1355–1361 1359other hand, some ntPTH fragments, such as PTH(7-84),
have been shown to bind a receptor other than the PTH/
PTHrP receptor and to antagonize the actions of full-length
PTH in vivo [7, 8, 10, 26, 27]. Thus, the current data
suggest a possible role for ntPTH fragments in parathyroid
and bone physiology. However, the clinical relevance of the
measurement of these fragments in the assessment and
management of secondary hyperparathyroidism remains to
be established.
Interestingly, Monier-Faugere et al. recently reported
higher values of PTH(1-84) and higher values of the
ratio of PTH(1-84)/ntPTH during treatment of adult
hemodialysis patients with CaCO3 and intravenous
paricalcitol than in those treated with CaCO3 and
intravenous calcitriol [16]. The discrepancy between their
findings and our results may be due to several factors,
such as the differential effects between paricalcitol and
doxercalciferol on parathyroid gland secretion, altered
bioavailability according to routes of administration (i.e.
oral vs. intravenous), differences between adults and
children, and/or the specific effect of the type of dialytic
modality (hemodialysis vs. peritoneal dialysis). One, or
more, of these factors may affect the bioavailability of
vitamin D sterols, alter calcium absorption, or change the
parathyroid gland’s response to therapy with active
vitamin D.
In conclusion, while treatment with both CaCO3 and
sevelamer were equally effective in controlling serum
phosphorus levels, treatment with CaCO3 resulted in
higher serum calcium levels. Higher doses of vitamin D
could thus be administered to patients treated with
sevelamer, resulting in equivalent suppression of PTH
[17], without increases in serum calcium. Two different
1st PTH-IMAs and a 2nd PTH-IMA were suppressed to a
similar degree, regardless of therapy. However, lower
serum calcium concentrations were associated with higher
values for the ratio of PTH(1-84)/ntPTH. Thus, while 2nd
PTH-IMAs specifically detect the “biologically active”
PTH(1-84) molecule and may provide new insights in
parathyroid gland physiology, the data reported here
suggest that 1st and 2nd PTH-IMAs are of equal clinical
utility for monitoring the response of secondary hyper-
parathyroidism to treatment with vitamin D analogues and
phosphate binders.
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